Drug Approval | March 12, 2026
FDA nod to first treatment for rare genetic brain disorder
The approval comes after a systematic review of published literature
The approval comes after a systematic review of published literature
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Giredestrant shows promise despite missing primary goal
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Germany will be the first launch market
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Subscribe To Our Newsletter & Stay Updated
